Burning Rock Biotech Limited (BNR) reports developments in next-generation sequencing technology for precision oncology. Its news commonly covers financial results, Form 20-F annual reporting, annual general meeting actions, ADS-related ownership announcements, and clinical or regulatory updates for NGS assays used in therapy selection, MRD assessment, companion diagnostics and cancer early detection.
Company updates reference products and technologies such as OncoScreen, CanCatch and ELSA-seq, including study publications, patent grants and companion-diagnostic approvals connected to precision oncology testing.
Burning Rock Biotech Limited (NASDAQ: BNR) announced the presentation of validation data for its fully-automated NGS library preparation platform, Magnis BR, at the AMP 2020 annual meeting on November 19, 2020. Co-developed with Agilent Technologies, Magnis BR enables hospitals to conduct NGS tests in-house with minimal space and staff requirements. It offers a streamlined 9-hour overnight preparation process, allowing for NGS report generation in as little as 3 days. As China's sole capture-based automated NGS system, it enhances Burning Rock's position in the in-hospital testing market.
Burning Rock Biotech Limited (NASDAQ: BNR) announced that new data for its ELSA-seq test will be presented at the ESMO Asia Virtual Congress on November 20. The ELSA-seq test focuses on early cancer detection through targeted methylation sequencing, which analyzes epigenetic changes in cell-free DNA. The THUNDER pilot study aims to develop and validate this test, showcasing results from the THUNDER-II substudy, which covers various cancers including those in the lung and pancreas. Burning Rock's mission is to enhance precision oncology using advanced sequencing technologies.
Burning Rock Biotech Limited (NASDAQ: BNR) announced plans to release its unaudited financial results for Q3 2020 on November 20, 2020, before U.S. market opening. The company anticipates revenues between RMB118 million (US$17.4 million) and RMB123 million (US$18.1 million), indicating a 16.2% year-over-year increase. Following the release, a conference call will be held to discuss the results, along with data on cancer early detection at the ESMO Asia Virtual Congress 2020. The revenue figures are preliminary and subject to change until finalization.
Burning Rock Biotech Limited (NASDAQ: BNR) will participate in the Morgan Stanley Virtual Healthcare Conference on September 17 at 8:00 a.m. Eastern Time. The company's management will engage in a fireside chat, allowing for inquiries through Morgan Stanley sales representatives. Burning Rock specializes in precision oncology using next-generation sequencing (NGS) technology, holding a leading market share in China for NGS-based therapy selection testing with over 185,000 tests conducted. The firm is also advancing NGS-based cancer early detection into clinical validation.
Burning Rock Biotech Limited (NASDAQ: BNR) reported a revenue of RMB107.0 million (US$15.1 million) for Q2 2020, a 26.1% increase year-over-year. The central laboratory revenue surged by 17.7% to RMB74.6 million, while in-hospital revenue grew 69% to RMB27.6 million. Despite increased revenues, the company recorded a net loss of RMB71.1 million, worsening from RMB26.0 million in 2019. Operating expenses rose significantly by 67.3% to RMB151.4 million, driven by higher research and development costs. The company expects full-year 2020 revenues of approximately RMB420 million, indicating a 28% growth in H2 2020.
Burning Rock Biotech Limited (NASDAQ: BNR) plans to announce its second quarter 2020 financial results on August 11, 2020, before the U.S. market opens. Following this, a conference call will take place at 8:00 a.m. ET to discuss the results. The company specializes in next-generation sequencing (NGS) technology for precision oncology, with a significant market presence in China, having completed over 185,000 tests. Burning Rock is committed to innovative NGS testing products and has received key certifications in laboratory quality systems.
On June 29, 2020, Burning Rock Biotech (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals to co-develop companion diagnostics for pralsetinib, aimed at detecting RET alterations in cancer patients in China. Pralsetinib, an investigational therapy by Blueprint Medicines, has shown promising clinical results, particularly in RET fusion-positive non-small cell lung cancer. Burning Rock is committed to advancing precision diagnostics leveraging next-generation sequencing technology, enhancing patient targeting for therapies.
Burning Rock Biotech Limited (NASDAQ: BNR) announced the full exercise of an over-allotment option in its IPO, allowing for the sale of an additional 2,025,000 American Depositary Shares (ADSs) at US$16.50 each. The total offering size now stands at approximately US$281.2 million. The company has a total of 103,804,534 ordinary shares post-offering, including 86,479,686 Class A shares. The IPO is facilitated by underwriters Morgan Stanley, BofA Securities, and Cowen.